Antihypertensive Drug Therapy with Captopril in Children and Adolescents

Publisher Website
Google Scholar
Abstract
Captopril was administered to three groups of hypertensive children and adolescents: 1) patients with renal disease; 2) neonates with umbilical artery related hypertension; and 3) post-renal transplant patients. In older children with renal disease, increasing the captopril dose above 0.5 mg/kg did not improve the antihypertensive response. A maximal drug concentrations occurred one hour after dosing, and captopril concentration returned to predose levels by eight hours. Neonates responded to significantly lower doses of captopril (0.01–0.5 mg/kg) and the duration of response to higher doses appeared to be longer than that observed in older children. In post-renal transplant patients, blood pressure decreased after captopril in 94% of subjects, but in 62% a concomitant increase in serum creatinine was observed (correlation [r]=0.55, p<.02). This increase could not be correlated with renal biopsy histopathology. Thus, captopril has proven to be an effective antihypertensive agent in children over a broad age range and for a variety of clinical conditons.